APPENDIX C - GRAPHICAL REPRESENTATION OF ANSWERS TO SELECTED QUESTIONS BY RESPONDENTS TO THE QUESTIONNAIRE SURVEY (SEE APPENDIX A) | Significant Findings from Full-Scale Accelerated Pavement Testing | The National Academies Press
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
CAT Normalization Process 2023: How Scaled Score is Calculated, Revised Process for 3 Shifts | CollegeDekho
Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registry - Martin Stangel, Ralf Gold, David Pittrow, Ulrich Baumann, Michael Borte, Maria Fasshauer, Manfred Hensel, Dörte Huscher,
Table 1 from Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies | Semantic Scholar
Clinician-rated measures for distal symmetrical axonal polyneuropathy | Neurology
Peripheral nerve ultrasonography in chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: correlations with clinical and neurophysiological data - Document - Gale OneFile: Health and Medicine
A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol. - Abstract - Europe PMC
Number of responders by the adjusted INCAT score at completion (ITT). | Download Table
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. | Semantic Scholar
Number of responders by the adjusted INCAT score at completion (ITT). | Download Table
Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study. - Abstract - Europe PMC
Assessment of INCAT, ISS, and MRC Scales Before and After Treatment... | Download Scientific Diagram
Comparing the NIS vs. MRC and INCAT sensory scale through Rasch analyses - Draak - 2015 - Journal of the Peripheral Nervous System - Wiley Online Library
Therapeutic Considerations for the Management of CIDP and MMN: Case Reviews
Corneal inflammatory cell infiltration predicts disease activity in chronic inflammatory demyelinating polyneuropathy | Scientific Reports
Chronic Inflammatory Demyelinating Polyneuropathy - Practical Neurology
Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy | BMC Neurology | Full Text
Clinical characteristics from CIDP patients with INCAT disability... | Download Table
Frontiers | Calprotectin in Chronic Inflammatory Demyelinating Polyneuropathy and Variants—A Potential Novel Biomarker of Disease Activity
![2009 Convegno Malattie Rare Benedetti [22 01] | PPT](https://image.slidesharecdn.com/2009convegnomalattierarebenedetti2201-090330145811-phpapp02/85/2009-convegno-malattie-rare-benedetti-22-01-12-320.jpg?cb=1670228110 "2009 Convegno Malattie Rare Benedetti [22 01] | PPT")
2009 Convegno Malattie Rare Benedetti [22 01] | PPT
03-Sep-19 1 PRACTICAL POINTS IN CIDP MANAGEMENT CONTENT CIDP KEY FEATURES
xmlinkhub
Changes in the Inflammatory Neuropathy Cause and Treatment (INCAT)... | Download Scientific Diagram
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Construction and validation of the chronic acquired polyneuropathy patient‐reported index (CAP‐PRI): A disease‐specific, health‐related quality‐of‐life instrument - Gwathmey - 2016 - Muscle & Nerve - Wiley Online Library
PDF) Validation of the Serbian version of inflammatory Rasch‐built overall disability scale in patients with chronic inflammatory demyelinating polyradiculoneuropathy | Mariëlle Pruppers - Academia.edu
